Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Effect of supercritical carbon dioxide fluid extract from Chrysanthemum indicum Linné on bleomycin-induced pulmonary fibrosis

BMC Complementary Medicine and Therapies volume 21, Article number: 240 (2021) Cite this article

Abstract

Background

As a prevalent type of cryptogenic fibrotic disease with high mortality, idiopathic pulmonary fibrosis (IPF) still lacks effective therapeutic drugs. The compounds extracted from buds and flowers of Chrysanthemum indicum Linné with supercritical-carbon dioxide fluid (CISCFE) has been confirmed to have antioxidant, anti-inflammatory, and lung-protective effects. This paper aimed to clarify whether CISCFE could treat IPF induced by bleomycin (BLM) and elucidate the related mechanisms.

Methods

Rats (Sprague-Dawley, male) were separated into the following groups: normal, model, pirfenidone (50 mg/kg), CISCFE-L, −M, and -H (240, 360, and 480 mg/kg/d, i.g., respectively, for 4 weeks). Rats were given BLM (5 mg/kg) via intratracheal installation to establish the IPF model. A549 and MRC-5 cells were stimulated by Wnt-1 to establish a cell model and then treated with CISCFE. Haematoxylin-eosin (H&E) and Masson staining were employed to observe lesions in the lung tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot (WB) were performed to observe changes in genes and proteins connected with the Wnt/β-catenin pathway.

Results

CISCFE inhibited the proliferation of MRC-5 cells (IC50: 2.723 ± 0.488 μg/mL) and A549 cells (IC50: 2.235 ± 0.229 μg/mL). In rats, A549 cells, and MRC-5 cells, BLM and Wnt-1 obviously induced the protein expression of α-smooth muscle actin (α-SMA), vimentin, type I collagen (collagen-I), and Nu-β-catenin. The mRNA levels of matrix metalloproteinase-3 (MMP-3) and − 9 (MMP-9), two enzymes that degrade and reshape the extracellular matrix (ECM) were also increased while those of tissue inhibitor of metalloproteinase 1 (TIMP-1) were decreased. However, CISCFE reversed the effects of BLM and Wnt-1 on the expression pattern of these proteins and genes.

Conclusion

These findings showed that CISCFE could inhibit IPF development by activating the Wnt/β-catenin pathway and may serve as a treatment for IPF after further investigation.

Peer Review reports

Background

Idiopathic pulmonary fibrosis (IPF), a prevalent fibrotic disease with high mortality, is a complex pathology of the lung with unknown aetiology [1, 2]. Previous studies have reported that inflammation occurs early following lung injury [3]. Excess inflammation and abnormal repair result in epithelial-mesenchymal transition (EMT) [4] and abnormal growth of lung interstitial cells, resulting in changes in the collagens deposed into the extracellular matrix (ECM) [5]. However, as IPF is a pulmonary disease characterized by progressive interstitial fibrosis, parenchymal inflammation and accumulation of ECM protein [6], the detailed cellular and molecular mechanisms of its development remain unknown. Currently, the main treatment strategies of IPF include glucocorticoids, antifibrinolytic agents, and antioxidants. The most commonly used drug is pirfenidone (PFD). However, PFD also has inevitable side effects [7, 8]. Thus, new potential targets and agents to ameliorate IPF urgently need to be identified and developed.

The Wnt signalling pathway participates in self-renewal of stem cells, metabolic disease, bone disease, and cancer [9]. Based on the different types of downstream effectors, there are two Wnt signalling pathways: the canonical pathway (Wnt/β-catenin) and the non-canonical pathway [10]. Emerging evidence has shown that the canonical pathway plays an active role in IPF development [11]. β-Catenin, as a necessary element of the canonical pathway, participates in the physiological process of EMT, which is a major process involved in fibrotic tissue repair after injury, tumour progression, and embryonic development [12]. The Wnt protein is critical in the canonical pathway. When lung tissue is damaged, Wnt protein expression can be stimulated, and subsequent downstream signal inhibits the phosphorylation of β-catenin and slows its degradation. Therefore, β-catenin accumulates in the cytoplasm and then translocates to the nucleus, where it regulates the expression of interrelated genes, including matrix metalloproteinases (MMPs) [13]. Moreover, it is known that matrix metalloproteinase-3 (MMP-3) and matrix metalloproteinase-9 (MMP-9) can degrade various ECM closely interrelated with the occurrence of IPF [14]. Therefore, the Wnt/β-catenin signalling pathway may affect the occurrence of IPF by affecting ECM deposition.

Chrysanthemum indicum Linné, a medicinal and edible plant, is mostly used in pharmaceutical products and in health products, beverages, and food additives. Clinically, it has been used to treat coronary heart disease, hypertension, and respiratory diseases such as pneumonia and bronchitis [15]. Many experimental data have confirmed that the extract of Chrysanthemum indicum Linné has antitumour [16], antioxidant [17], antimicrobial [18], anti-inflammatory, and immunomodulatory effects [19, 20]. The supercritical carbon dioxide extraction is widely used to extract chemical constituents from Chrysanthemum indicum Linné, not only because the supercritical carbon dioxide extraction is efficient and environmentally friendly, but also because it can obtain more biologically active compounds and ensure the structural integrity of volatile compounds. Specifically, the extract from buds and flowers of Chrysanthemum indicum Linné in supercritical carbon dioxide fluid (CISCFE) has been widely used in cosmetics, functional foods, and toiletries [21]. Moreover, our previous study showed that it could enhance the antitumour effect and reduce pulmonary damage of bleomycin (BLM) [22]. In addition, CISCFE has been demonstrated to protect against UV-induced skin injury and lipopolysaccharide (LPS)-induced lung injury [23, 24] We previously observed that CISCFE can significantly inhibit inflammatory cytokines induced by LPS and produced by alveolar epithelial cells, thereby alleviating LPS-mediated lung injury [24]. When CISCFE and BLM were administered together to treat tumours, we found that BLM combined with CISCFE could remarkably attenuate collagen deposition and inflammatory damage in lung tissues. Based on the above findings, we hypothesized that CISCFE has a lung protective effect. However, whether CISCFE could be used to treat IPF remains unknown.

In this study, to determine whether CISCFE could relieve or treat pulmonary fibrosis, we used a BLM-induced IPF model and Wnt-1-induced cell model to verify this hypothesis.

Methods

Antibodies and reagents

DMEM, RPMI 1640 medium, foetal bovine serum (FBS) and phosphate-buffered solution (PBS) was provided by Gibco (Grand Island, NY, USA). Hydroxyproline (HYP) assay kits were obtained from Shanghai Kejian Biology Science and Technology Co., Ltd. (Shanghai, China). Penicillin-streptomycin was provided by HyClone (Logan, UT, USA). Poly-clonal antibodies targeting GAPDH (AF7021), Histone H3 (AF0863), α-smooth muscle actin (α-SMA, AF1032), vimentin (AF7013), β-catenin (AF6266), and type I collagen (collagen-I, AF7001) as well as HRP-labelled Goat Anti-Rabbit lgG antibodies (E030120–01) were obtained from Affinity Biosciences (OH, USA).

Drugs

We dissolved BLM (Zhejiang Hai Zheng Pharmaceuticals, China. purity> 99%) in 0.9% normal saline. CISCFE (Lot. 20,121,104) was manufactured by the Mathematical Engineering Academy of Chinese Medicine at the Guangzhou University of Chinese Medicine. We analysed the CISCFE composition using high-performance liquid chromatography with a photodiode array detector (HPLC-PAD) and gas chromatography-mass spectrometry (GC-MS) [24]. GC-MS detected thirty unique compounds, and HPLC-PAD identified five compounds (Supplementary Materials 1). CISCFE was suspended in 0.9% normal saline containing 3% Tween 80 as a cosolvent. Pirfenidone was provided by Dalian Meilun Biological Technology Co., Ltd. (lot number: A0730A; Dalian, China). Normal saline (0.9%) was used to dissolve pirfenidone.

Procedure for supercritical-carbon dioxide fluid extraction

Chrysanthemum indicum Linné was purchased from Guangzhou Qingping medicinal materials market (Guangzhou, China), authenticated based on its microscopic and macroscopic characteristics. Chrysanthemum indicum Linné was placed in the extraction kettle (5 L-SFE, Guangzhou Institute of Light Industry), and then reflux extraction for 3 h under the condition of 25 MPa, 45 °C and the flow rate of CO2 was 30 kg/h.

Cells

The Cell Bank of the Chinese Academy of Science provided the MRC-5 cells (human lung fibroblasts cell line) and A549 cells (adenocarcinoma of human alveolar epithelial cell line). Cells were cultured in DMEM/RPMI 1640 medium, which included 1% penicillin-streptomycin and 10% FBS, at 37 °C and 5% CO2.

Cytotoxicity assay

A549 cells (1 × 104 cells/well) and MRC-5 cells (0.75 × 104 cells/well) were seeded in 96-well plates for MTS detection. Then, the medium was replaced with medium containing CISCFE (20, 40, 60, 80, 100, 200, 400, 800, or 1000 ng/mL). MTS (20 μL) was employed after cells were cultured for 24/48 h. Four hours later, cell viabilities were measured at 492 nm using a multimode plate reader. The IC50 of CISCFE in the two cell lines was calculated using GraphPad Prism software (version 6).

The effects of different doses of Wnt-1 (5, 10, 15, 20, 30, 40, 60, and 100 ng/mL) on A549 and MRC-5 cells were also studied using MTS. Cells were seeded into 96-well plates determine cell viability. Serum-free medium was added when the cells adhered. Then, the cells were stimulated with 20 ng/mL Wnt-1 for 24 h after serum starvation for 6 h. Then, the cells were treated with medium containing 400 ng/mL CISCFE. Cells were assessed after 24 h of treatment.

Experimental animal procedures and pulmonary fibrosis model establishment

The Experimental Animal Centre of Guangzhou University of Chinese Medicine (Certificate number 44005800005378, Guangzhou, China) provided male adult Sprague-Dawley (SD) rats. The procedures were conducted under the guidance of the Animal Care and Welfare Committee of Guangzhou University of Chinese Medicine. Rats were placed in an SPF environment (temperature 24–26 °C, humidity 70–75%). Rats were provided free access to food and water. The animal experiments were conducted according to the guidelines established by the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.

Sixty rats were randomly assigned to the following six groups (n = 10; group by random number table method): normal, model, PFD, CISCFE-L, −M, and -H. Except for rats in the control group, all the rats were given BLM (5 mg/kg) via intratracheal installation to establish a pulmonary fibrosis model. Three days after BLM injection, intragastric administration was started. Normal saline was administered to rats in the normal and model groups. PFD (50 mg/kg) was given to rats in the PFD group, and rats in the CISCFE-L, −M, and -H groups were treated with CISCFE (240, 360, and 480 mg/kg, respectively). All drugs were intragastrically administered once per day. During the experiment, none of the rats died.

After 28 days, all rats were weighed and administered 1% pentobarbital sodium (40 mg/kg) via intraperitoneal injection. Then, the rats were sacrificed by bleeding from the abdominal aorta, and the lung tissues were rapidly collected and washed with ice-cold normal saline. The lung tissues were weighed, and the left lung tissues (0.1 g) of all rats were fixed with 4% paraformaldehyde. The remaining lung tissue was stored at − 80 °C.

Relative lung weight and body weight changes

The relative lung weight was calculated as follows: lung coefficient = lung weight (g)/body weight (kg) × 100%.

Histological analysis

After fixation for 24 h, the fixed lung tissue was dehydrated with different concentrations of alcohol, and different xylenes were used for transparency. Then, lung tissues were embedded in paraffin. After the paraffin was cooled, 5 μm sections were cut to observe inflammatory infiltration and collagen deposition with haematoxylin-eosin (H&E) and Masson’s trichrome staining, respectively. Then, the stained sections were observed under a microscope. The grades of pathologic changes that indicated lung injury were evaluated referencing others’ reports [25, 26]. Lung injury includes oedema, congestion, inflammatory cell infiltration, and interstitial inflammation, each of which was graded from 0 to 4. The scores of each category per individuals were added to the final score of lung injury.

HYP analysis

Lung tissues (0.1 g) were homogenized in HYP Assay Kit hydrolysate using a tissue homogenizer. After halting the hydrolysate reaction according to the manufacturer’s instructions, the absorbance of the supernatant was measured at 550 nm on a spectrophotometer.

Cell transfection and treatment

MRC-5 (1 × 105 cells/mL) and A549 (1.25 × 105 cells/mL) cells were seeded into 6-well plates. Then, the cells were stimulated with Wnt-1 (20 ng/mL) when they reached 70–80% confluence. After incubation for 24 h, cells were treated with medium containing CISCFE (400 ng/mL). RNA and protein were extracted after 24 h.

The small interfering RNA (siRNA) targeting β-catenin and the negative control were provided by RiboBio (Guangzhou, China). Lipofectamine 2000 (Invitrogen) was adopted to transfect β-catenin siRNA (40 nM) or negative control siRNA into the cells according to the manufacturer’s instructions. Then, the cells were treated as described above.

Quantitative real-time polymerase chain reaction (qRT-PCR)

We extracted total RNA from two kinds of cells and lung tissues with TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. Ultra-micro spectrophotometer (Thermo Fisher Scientific, USA) was used to measure the purity and concentration of extracted RNA. When the OD260/OD280 value was in the range of 1.8 ~ 2.1, the RNA purity is considered to meet the experimental requirements. A reverse transcription kit (Vazyme Biotech Co., Ltd., China) was applied to reverse transcribe total RNA. The cDNA of two cells and lung tissues were stored at − 20 °C. Then, qRT-PCR amplification was accomplished using a ChamQ™ Universal SYBR qPCR Master Mix Kit (Vazyme Biotech Co., Ltd., China) under the following cycling conditions: 95 °C for 30 s followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 60 s. The respective primers are listed in Table 1. GAPDH served as the reference gene. This study employed the 2-∆∆Ct method to calculate gene expression based on the following formula: Fold change = 2-∆∆Ct, ∆∆Ct = (CtSample - CtGAPDH) - (CtControl - CtGAPDH).

Table 1 Primers sequences employed for quantitative PCR
Full size table

Western blotting

Total proteins were extracted from two kinds of cells and lung tissues with radio-immunoprecipitation assay (RIPA) buffer, and the proteins from the nuclear and cytoplasmic fractions of two cells and lung tissues were obtained with a Nuclear and Cytoplasmic Protein Extraction Kit (Keygen Biotech, Jiangsu, China). The protein concentrations of all the samples were estimated using the Bicinchoninic Acid Protein Kit (Best Bio, Shanghai, China). Fifty micrograms of two cells and lung tissues proteins were resolved using SDS-PAGE on 12% or 8% gels and were transferred onto PVDF membranes (Millipore, Billerica, USA). The membranes were blocked with 5% non-fat milk for 1 h. The membranes were incubated with anti-GAPDH (1:1000), anti-H3 (1:1500), anti-α-SMA (1:500), anti-vimentin (1:500), anti-β-catenin (1:500) and anti-collagen-I (1:500) antibodies overnight at 4 °C. Then, the membranes were treated with secondary antibodies (1:2000) for 2 h. Protein expression of two cells and lung tissues were measured by a chemiluminescence system (Tanon). The band densities of GAPDH and H3 were used as a reference.

Statistical analysis

SPSS 23.0 software was used to analyse the results, and the data are expressed as the means ± SD. Duncan’s test and one-way ANOVA were used to analyse the statistical significance among different groups. P < 0.05 was considered statistically significant.

Results

Effects of Wnt-1 and CISCFE on MRC-5 and A549 cells

Figure 1 shows that the growth rates of A549 (1A) and MRC-5 cells (1B) were obviously faster after cells were treated with Wnt-1 (5, 10, 15, 20, 30, 40, 60, and 100 ng/mL) for 24 h or 48 h. However, CISCFE significantly inhibited the proliferation of A549 cells (IC50: 2.723 ± 0.488 μg/mL) (1C) and MRC-5 cells (IC50: 2.236 ± 0.230 μg/mL) (1D).

Fig. 1
figure 1

Effects of Wnt-1 and CISCFE on A549 and MRC-5 cells. Effects of treatment with Wnt-1 (5, 10, 15, 20, 30, 40, 60, or 100 ng/mL) on A549 (A) and MRC-5 cells (B). Effects of treatment with CISCFE (20, 40, 60, 80, 100, 200, 400, 800, and 1000 ng/mL) on A549 (C) and MRC-5 cells (D). The viability of A549 cells (E) and MRC-5 cells (F) was measured after stimulation with Wnt-1 (20 ng/mL) for 24 h followed by administration of CISCFE (20, 40, 60, 80, 100, 200, and 400 ng/mL). Cell viability is presented as the mean ± SD. (n = 6). a, P < 0.05; aa, P < 0.01 vs the control group. b, P < 0.05 bb, P < 0.01 and bbb, P < 0.001 vs the Wnt-1 group

Full size image

Figure 1E, F shows that compared with the Wnt-1 alone group, the CISCFE (80, 100, 200, 400 ng/mL) groups showed significantly reduced cell viability (P < 0.05). The data illustrated that CISCFE can significantly suppress Wnt-1-mediated proliferation of A549 cells and MRC-5 cells. Based on these results, Wnt-1 (20 ng/mL) and CISCFE (400 ng/mL) were utilized for subsequent experiments.

Effect of CISCFE on relative lung weight and level of HYP in BLM-treated rats

We analysed the effect of CISCFE on the experimental rat lung coefficient. BLM upregulated the lung coefficient (P < 0.05) (Fig. 2A). However, after CISCFE treatment, the lung coefficient value of rats significantly decreased.

Fig. 2
figure 2

Effect of CISCFE on the relative lung weight and HYP level of BLM-treated rats. A Relative lung weight of BLM-treated rats. B Effect of CISCFE on HYP levels in BLM-treated rat lung tissues. The results are shown as the means ± SD. (n = 8). ##, P < 0.01 vs the normal group; *, P < 0.05 and **, P < 0.01 vs the model group

Full size image

HYP is the principal constituent of collagen. The degree of IPF can be reflected by the content of HYP. Figure 2B shows that CISCFE-M and -H treatment can reduce the HYP level.

Effect of CISCFE on IPF in BLM-treated rats

The model group showed significant inflammation, collagen deposition and severely damaged lung tissue structure (Fig. 3A, B). The CISCFE-M and -H groups showed that the above situation was relieved after treatment compared with the model group. Figure 3C shows that BLM can obviously induce lung injury in rats. However, CISCFE-M and CISCFE-H alleviated the lung injury caused by BLM in rats (P < 0.05). These results indicated that CISCFE can alleviate IPF caused by BLM to a certain extent.

Fig. 3
figure 3

Effect of CISCFE attenuated BLM-induced IPF. A Observation of inflammation (× 200). B Observation of collagen deposition (× 200). C Lung injury score. Scale bar indicates 100 μm. The results are shown as the means ± SD. (n = 4). ##, P < 0.01 vs the normal group; *, P < 0.05 and **, P < 0.01 vs the model group

Full size image

Effect of CISCFE on the expressions of α-SMA, Vimentin, collagen-I, nu-β-catenin in A549 cells, MRC-5 cells and BLM-treated rats

In this study, BLM obviously increased α-SMA, vimentin, collagen-I and Nu-β-catenin protein expression in A549 cells (Fig. 4A) and MRC-5 cells (Fig. 4B) (P < 0.05). The expression of these proteins was downregulated in A549 and MRC-5 cells treated with CISCFE. In addition, Fig. 4C shows that the expression of the above proteins in BLM-treated rat lung tissues was decreased in the CISCFE-M and -H groups (P < 0.05). Thus, CISCFE relieved the abnormal deposition of ECM proteins in BLM-treated rats.

Fig. 4
figure 4

Effect of CISCFE on α-SMA, Vimentin, Collagen-I, Nu-β-catenin expression in A549, MRC-5 cells and BLM-treated rats. A Effect of CISCFE on the expression of α-SMA, Vimentin, Collagen-I, Nu-β-catenin in A549 cells. B Effect of CISCFE on the expression of α-SMA, Vimentin, Collagen-I, and Nu-β-catenin in MRC-5 cells. C Effect of CISCFE on the expression of α-SMA, Vimentin, Collagen-I, and Nu-β-catenin in BLM-treated rat lung tissues. The relative expression of Nu-β-catenin is shown as the ratio relative to H3 expression. The results are presented as the mean ± SD. (n = 3). To fit into the manuscript properly, the gel was reasonably trimmed. aa, P < 0.01 vs the control group; b, P < 0.05, bb, P < 0.01 vs the Wnt-1 group. ##, P < 0.01 vs the normal group; *, P < 0.05 and **, P < 0.01 vs the model group

Full size image

Effect of CISCFE on MMP-3, MMP-9 and TIMP-1 mRNA levels in A549 cells, MRC-5 cells and BLM-treated rats

A549 cells and MRC-5 cells treated with CISCFE showed downregulation of MMP-3 (Fig. 5A), MMP-9 (Fig. 5B), and TIMP-1(Fig. 5C) mRNA levels (P < 0.05), when compared with Wnt-1 group. After treatment with CISCFE-M or CISCFE-H, MMP-3 (Fig. 5D) and MMP-9 (Fig. 5E), and TIMP-1(Fig. 5F) mRNA levels were decreased (P < 0.05) in BLM-treated rats, compared with model group. The data showed that IPF induced by BLM can be relieved by CISCFE by affecting the gene expression associated with abnormal deposition of collagen in the ECM.

Fig. 5
figure 5

Effect of CISCFE on MMP-3, MMP-9 and TIMP-1 mRNA levels in A549 cells, MRC-5 cells and BLM-treated rats. Effect of CISCFE MMP-3 (A), MMP-9 (B) and TIMP-1 (C) mRNA levels in A549 and MRC-5 cells was observed. The influence of the CISCFE on MMP-3 (D), MMP-9 (E) and TIMP-1 (F) mRNA levels in BLM-treated rats was noted. The results are presented as the means ± SD. (n = 6). aa, P < 0.01 vs the control group; b, P < 0.05 and bb, P < 0.01 vs the Wnt-1 group. ##, P < 0.01 vs the normal group; *, P < 0.05 and **, P < 0.01 vs the model group

Full size image

Effect of CISCFE on the Wnt/β-catenin Signalling pathway in A549 and MRC-5 cells following β-catenin siRNA knockdown

Figure 6 shows that α-SMA, vimentin, collagen-I, and Nu-β-catenin protein expression were unchanged following β-catenin siRNA knockdown in A549 cells (Fig. 6A) and MRC-5 cells (Fig. 6B) when cells were treated with Wnt-1 (20 ng/mL) for 24 h. After treatment with CISCFE, the expression of the above proteins was also unchanged in both cell lines when β-catenin was knocked down compared with the wnt-1 group. The data illustrated that CISCFE adjusted the Wnt/β-catenin signalling pathway to alleviate the process of IPF.

Fig. 6
figure 6

Effect of CISCFE on the Wnt/β-catenin signalling pathway in A549 and MRC-5 cells following siRNA-mediated β-catenin knockdown. A Effect of CISCFE on the Wnt/β-catenin signalling pathway in A549 cells. B Effect of CISCFE on the Wnt/β-catenin signalling pathway in MRC-5 cells. The results are presented as the means ± SD. (n = 3). To fit into the manuscript properly, the gel was reasonably trimmed. a, P < 0.05 vs control group

Full size image

Discussion

IPF is a pulmonary interstitial disease with a high mortality rate. Currently, both the morbidity and mortality of IPF has increased year after year. Even the mortality rate is higher than that of most tumours. However, owing to the poorly understood potential pathogenesis of IPF, there is still a lack of drugs that can completely cure IPF. Our previous study illustrated that CISCFE can improve the antitumour effect of BLM while simultaneously attenuating its toxicity effects and CISCFE could inhibit acute lung injury induced by LPS [22, 24, 27]. This current study clarified that CISCFE can inhibit IPF development by affecting the balance of the Wnt/β-catenin pathway.

IPF is caused by a variety of factors. The idea that abnormal ECM deposition is a cardinal feature of pulmonary fibrosis has been generally accepted. The ECM, which comprises collagens, proteoglycans, elastin, and other molecules, is involved in proper lung function. Myofibroblasts have been confirmed to contribute to ECM accumulation in vivo and in vitro [28]. Studies have found that both epithelial cells and fibroblasts in the lungs can transform into myofibroblasts through EMT, which is the process by which epithelial cells transform into mesenchymal cells. According to molecular and functional characterization, EMT is divided into three categories: type I EMT related to embryogenesis, type II EMT linked to fibrosis and wound healing and type III EMT involved in cancer metastasis [29]. It is generally accepted that type II EMT has a substantial effect on the development of IPF [30, 31]. In addition, studies have shown that the occurrence of EMT is accompanied by an increase in the expression of a mesenchymal phenotype marker (vimentin) and abnormal deposition of ECM proteins, such as α-SMA and collagen-I [32, 33]. MRC-5 cells, a cell line that retains the biochemical characteristics of lung fibroblasts, are commonly utilized as lung fibroblast cells in pulmonary fibrosis research [34, 35]. Although the A549 cell line is a human-derived lung adenocarcinoma cell line, it is widely used to establish an EMT model by stimulating the cells with Wnt-1 or other cytokines [36, 37] because its morphology and basic cell functions are similar to those of human alveolar type II epithelial cells. Therefore, to investigate whether CISCFE could affect the transformation of epithelial cells and fibroblasts to myofibroblasts in vitro, we used A549 cells and MRC-5 cells to establish a cell model. MRC-5 cells were treated with Wnt-1 to establish a cell transdifferentiation model, and A549 cells were stimulated by Wnt-1 to establish an EMT model. Our experimental results indicated that CISCFE could significantly decrease vimentin, α-SMA and collagen-I expression in A549 cells, MRC-5 cells, and lung tissues of BLM-induced IPF rats. The data illustrated that BLM-induced IPF could be inhibited by CISCFE via suppression of EMT and abnormal ECM deposition.

MMPs and tissue inhibitors of metalloproteinases (TIMPs) have been reported to participate in the formation and degradation of the ECM. MMPs are multidomain enzymes that have outstanding roles during the cleavage of constituents of the ECM. Twenty-four MMP genes have been identified in humans, and 8 MMPs have been implicated in IPF development. Not only did in vitro studies indicate that there was high expression of MMP-3 in the alveolar epithelial cells and lungs of IPF patients, but in vivo studies have also confirmed this phenomenon. Researchers observed high expression of MMP-9 in the lung tissues of IPF patients. Additionally, TIMPs are endogenous inhibitors that control the catalytic activity of MMPs. Usually, under normal physiological conditions, the ratio of MMPs to TIMPs is approximately 1:1, but under pathological conditions, this balance may be destroyed, leading to excessive deposition of ECM components [38]. Therefore, an imbalance of MMPs/TIMPs is associated with IPF. Studies have shown that not only MMP-3 levels but also MMP-9 levels were increased in IPF lungs [39]. TIMP-1 levels were also upregulated in IPF lungs but to a lesser extent than those of MMP-3 [40]. Y. Wang et al. [41] found that artesunate could inhibit the occurrence of IPF by decreasing MMP-3, MMP-9 and TIMP-1 levels. Hai-Tao Zhang et al. [42] confirmed that the balance of MMP-9/TIMP-1 expression in IPF patients was disrupted, and this ratio was obviously higher than that in normal patients. After glucocorticoid intervention, the MMP-9/TIMP-1 ratio in IPF patients was restored closer to homeostatic levels, and the MMP-9 and TIMP-1 levels were reduced. The experimental data indicated that CISCFE could significantly decrease MMP-3 and MMP-9 mRNA levels in the lung tissues of BLM-induced IPF rats and in A549 and MRC-5 cells. At the same time, the level of TIMP-1 gene expression could also be downregulated by CISCFE. The MMP/TIMP ratio was also decreased after CISCFE treatment. These data illustrated that CISCFE could inhibit the progression of BLM-induced IPF by regulating the imbalance of MMPs/TIMPs, which facilitates the elimination of abnormal ECM deposition.

Even though we know that EMT and the ECM are closely related to IPF development, we still have a poor understanding of the clear mechanism by which EMT and the ECM influences IPF. Recently, compelling evidence has revealed that Wnt/β-catenin reactivation is connected with EMT and the ECM [43, 44]. The Wnt/β-catenin pathway participates in adult stem cell maintenance, embryonic development and homeostasis [45, 46]. However, its abnormal activation leads to the progression of carcinomas of the liver, colon, lung and other organs [47,48,49]. Recently, some studies have shown that its abnormal activation is also involved in fibrotic diseases, such as IPF and renal fibrosis [13, 50, 51]. Therefore, Wnt/β-catenin signalling is considered a promising new target in the treatment of fibrotic disease [52]. In addition, the Wnt/β-catenin pathway was shown to be involved in the process of ECM deposition and EMT induction. Therefore, we speculated that CISCFE could inhibit the progression of BLM-induced IPF by downregulating the balance of the Wnt/β-catenin pathway. Studies have confirmed that β-catenin is a critical element of the Wnt/β-catenin pathway [53]. When external factors stimulate the tissue, β-catenin translocates to and accumulates in the nucleus, thereby activating the entire Wnt/β-catenin pathway. Van et al. [54] confirmed that β-catenin accumulated in the cell nucleus of lung tissues from IPF patients. Liang [55] also confirmed that during myofibroblast proliferation, β-catenin levels would increase in the nuclei of lung tissue cells. Our results showed that in the cell nuclei of lung tissues, β-catenin expression can be improved by BLM. However, CISCFE could inhibit this phenomenon. Based on the above results, we hypothesize that CISCFE affects IPF by regulating the balance of Wnt/β-catenin pathway activity.

To confirm the hypothesis that CISCFE could inhibit the progression of BLM-induced IPF by downregulating Wnt/β-catenin pathway activation, we used MRC-5 cells and A549 cells to investigate whether CISCFE could affect BLM-induced IPF after knockdown of the β-catenin gene. The β-catenin gene is a key gene in the Wnt/β-catenin pathway which will only be activated when β-catenin transferred into the cell nucleus. Therefore, we knockdown single gene β-catenin to block the activation of Wnt/β-catenin pathway. Human β-catenin siRNA was transfected into MRC-5 and A549 cells. The study results illustrated that CISCFE could suppress vimentin, α-SMA, β-catenin and collagen-I expression in Wnt-1-treated MRC-5 and A549 cells. By contrast, in MRC-5 and A549 cells transfected with β-catenin siRNA, CISCFE did not affect vimentin, α-SMA, β-catenin or collagen-I expression levels. The results revealed that CISCFE could inhibit the progression of BLM-induced IPF by influencing the balance of the Wnt/β-catenin pathway.

Our study still has some limitations. The pathogenesis of IPF is quite complicated. In this study, we investigated whether CISCFE inhibited IPF by downregulating Wnt/β-catenin pathway activity. However, we have not studied whether the attenuating effect of CISCFE is related to other signalling pathways. In addition, we have not studied the specific components in CISCFE that elicited these changes. Therefore, further research regarding these issues is necessary, and we will continue to study the issues related to the attenuating effect of CISCFE on IPF.

Conclusions

CISCFE could alleviate IPF induced by BLM. The studies demonstrated that CISCFE could alleviate EMT by adjusting the balance of the Wnt/β-catenin pathway and ultimately attenuate BLM-induced IPF. These results illustrated that after further research, CISCFE could become a potential drug for IPF.

Availability of data and materials

The data set used and analyzed in the study can be obtained from the corresponding author on reasonable request.

Abbreviations

BLM:

Bleomycin

CISCFE :

The extract extracted from buds and flowers of Chrysanthemum indicum Linné with supercritical-carbon dioxide fluid

Collagen- I:

Type I collagen

EMT:

Epithelial-mesenchymal transition

ECM:

Extracellular matrix

HYP:

Hydroxyproline

IPF:

Idiopathic pulmonary fibrosis

LPS:

Lipopolysaccharide

MMP-3:

Matrix metalloproteinase-3

MMP-9:

Matrix metalloproteinase-9

PFD:

Pirfenidone

RT-PCR:

Reverse Transcription-Polymerase Chain Reaction

SD:

Sprague-Dawley

TIMP-1:

Tissue inhibitor of metalloproteinase 1

WB:

Western blot

α-SMA:

α-smooth muscle actin

References

  1. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis - clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4):1301–15. https://doi.org/10.1164/ajrccm.157.4.9707039.

    Article  CAS  PubMed  Google Scholar 

  2. Barkauskas CE, Noble PW. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. Am J Physiol-Cell Physiol. 2014;306(11):C987–96. https://doi.org/10.1152/ajpcell.00321.2013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kandhare AD, Bodhankar SL, Mohan V, et al. Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-kappa B, Muc5ac, TNF-alpha, and IL-1 beta. Chem Biol Interact. 2015;237:151–65. https://doi.org/10.1016/j.cbi.2015.06.019.

    Article  CAS  PubMed  Google Scholar 

  4. Dong XW, Jia YL, Ge LT, et al. Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways. Toxicology. 2017;389:31–41. https://doi.org/10.1016/j.tox.2017.07.002.

    Article  CAS  PubMed  Google Scholar 

  5. Cui K, Kou JQ, Gu JH, et al. Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress. BMC Complement Altern Med. 2014;14(11). https://doi.org/10.1186/1472-6882-14-461.

  6. Tawfik MK, Makary S. 5-HT7 receptor antagonism (SB-269970) attenuates bleomycin-induced pulmonary fibrosis in rats via downregulating oxidative burden and inflammatory cascades and ameliorating collagen deposition: comparison to terguride. Eur J Pharmacol. 2017;814:114–23. https://doi.org/10.1016/j.ejphar.2017.08.014.

    Article  CAS  PubMed  Google Scholar 

  7. Behr J. Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(128):163–8. https://doi.org/10.1183/09059180.00001013.

    Article  PubMed  Google Scholar 

  8. Brown SW, Dobelle M, Padilla M, et al. Idiopathic pulmonary fibrosis and lung cancer a systematic review and meta-analysis. Ann Am Thoracic Society. 2019;16(8):1041–51. https://doi.org/10.1513/AnnalsATS.201807-481OC.

    Article  Google Scholar 

  9. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149(6):1192–205. https://doi.org/10.1016/j.cell.2012.05.012.

    Article  CAS  PubMed  Google Scholar 

  10. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13(12):767–79. https://doi.org/10.1038/nrm3470.

    Article  CAS  PubMed  Google Scholar 

  11. Kim TH, Kim SH, Seo JY, et al. Blockade of the Wnt/beta-catenin pathway attenuates bleomycin-induced pulmonary fibrosis. Tohoku J Exp Med. 2011;223(1):45–54. https://doi.org/10.1620/tjem.223.45.

    Article  CAS  PubMed  Google Scholar 

  12. Lam AP, Flozak AS, Russell S, et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45(5):915–22. https://doi.org/10.1165/rcmb.2010-0113OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hwang I, Seo EY, Ha H. Wnt/beta-catenin signaling: a novel target for therapeutic intervention of fibrotic kidney disease. Arch Pharm Res. 2009;32(12):1653–62. https://doi.org/10.1007/s12272-009-2200-3.

    Article  CAS  PubMed  Google Scholar 

  14. Sasaki M, Kashima M, Ito T, et al. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1 beta and TNF-alpha. Mediat Inflamm. 2000;9(3–4):155–60. https://doi.org/10.1080/09629350020002895.

    Article  CAS  Google Scholar 

  15. Kim C, Kim MC, Kim SM, et al. Chrysanthemum indicum L. extract induces apoptosis through suppression of constitutive STAT3 activation in human prostate cancer DU145 cells. Phytother Res. 2013;27(1):30–8. https://doi.org/10.1002/ptr.4689.

    Article  CAS  PubMed  Google Scholar 

  16. Li ZF, Wang ZD, Ji YY, et al. Induction of apoptosis and cell cycle arrest in human HCC MHCC97H cells with Chrysanthemum indicum extract. World J Gastroenterol. 2009;15(36):4538–46. https://doi.org/10.3748/wjg.15.4538.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kim IS, Ko HM, Koppula S, et al. Protective effect of Chrysanthemum indicum Linne against 1-methyl-4-phenylpridinium ion and lipopolysaccharide-induced cytotoxicity in cellular model of Parkinson's disease. Food Chem Toxicol. 2011;49(4):963–73. https://doi.org/10.1016/j.fct.2011.01.002.

    Article  CAS  PubMed  Google Scholar 

  18. Aridogan BC, Baydar H, Kaya S, et al. Antimicrobial activity and chemical composition of some essential oils. Arch Pharm Res. 2002;25(6):860–4.

    Article  CAS  Google Scholar 

  19. Lee DY, Choi G, Yoon T, et al. Anti-inflammatory activity of Chrysanthemum indicum extract in acute and chronic cutaneous inflammation. J Ethnopharmacol. 2009;123(1):149–54. https://doi.org/10.1016/j.jep.2009.02.009.

    Article  PubMed  Google Scholar 

  20. Cheng WM, Li J, You TP, et al. Anti-inflammatory and immunomodulatory activities of the extracts from the inflorescence of Chrysanthemum indicum Linne. J Ethnopharmacol. 2005;101(1–3):334–7. https://doi.org/10.1016/j.jep.2005.04.035.

    Article  PubMed  Google Scholar 

  21. Wu XL, Li CW, Chen HM, et al. Anti-inflammatory effect of supercritical-carbon dioxide fluid extract from flowers and buds of Chrysanthemum indicum Linnen. Evid-based Complement Altern Med. 2013;13. https://doi.org/10.1155/2013/413237.

  22. Yang HM, Sun CY, Liang JL, et al. Supercritical-carbon dioxide fluid extract from Chrysanthemum indicum enhances anti-tumor effect and reduces toxicity of bleomycin in tumor-bearing mice. Int J Mol Sci. 2017;18(3):15. https://doi.org/10.3390/ijms18030465.

    Article  CAS  Google Scholar 

  23. Zhang X, Xie YL, Yu XT, et al. Protective effect of super-critical carbon dioxide fluid extract from flowers and buds of Chrysanthemum indicum Linnen against ultraviolet-induced photo-aging in mice. Rejuvenation Res. 2015;18(5):437–48. https://doi.org/10.1089/rej.2014.1651.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wu XL, Feng XX, Li CW, et al. The protective effects of the supercritical-carbon dioxide fluid extract of Chrysanthemum indicum against lipopolysaccharide-induced acute lung injury in mice via modulating toll-like teceptor 4 signaling pathway. Mediat Inflamm. 2014;13. https://doi.org/10.1155/2014/246407.

  25. Szapiel SV, Elson NA, Fulmer JD, et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 1979;120(4):893–9. https://doi.org/10.1164/arrd.1979.120.4.893.

    Article  CAS  PubMed  Google Scholar 

  26. Liu Y, Wu H, Nie YC, et al. Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-kappa B pathway. Int Immunopharmacol. 2011;11(10):1606–12. https://doi.org/10.1016/j.intimp.2011.05.022.

    Article  CAS  PubMed  Google Scholar 

  27. Hosseini S, Imenshahidi M, Hosseinzadeh H, et al. Effects of plant extracts and bioactive compounds on attenuation of bleomycin-induced pulmonary fibrosis. Biomed Pharmacother. 2018;107:1454–65. https://doi.org/10.1016/j.biopha.2018.08.111.

    Article  CAS  PubMed  Google Scholar 

  28. Shimbori C, Gauldie J, Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr Opin Pulm Med. 2013;19(5):446–52. https://doi.org/10.1097/MCP.0b013e328363f4de.

    Article  CAS  PubMed  Google Scholar 

  29. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81. https://doi.org/10.1083/jcb.200601018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jolly MK, Ward C, Eapen MS, et al. Epithelial-mesenchymal transition, a spectrum of states: role in lung development, homeostasis, and disease. Dev Dyn. 2018;247(3):346–58. https://doi.org/10.1002/dvdy.24541.

    Article  PubMed  Google Scholar 

  31. Han Q, Lin LJ, Zhao BL, et al. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2018;500(4):839–45. https://doi.org/10.1016/j.bbrc.2018.04.148.

    Article  CAS  PubMed  Google Scholar 

  32. Su SD, Cong SG, Bi YK, et al. Paraquat promotes the epithelial-mesenchymal transition in alveolar epithelial cells through regulating the Wnt/beta-catenin signal pathway. Eur Rev Med Pharmacol Sci. 2018;22(3):802–9. https://doi.org/10.26355/eurrev_201802_14316.

    Article  PubMed  Google Scholar 

  33. Kolahian S, Fernandez IE, Eickelberg O, et al. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2016;55(3):309–22. https://doi.org/10.1165/rcmb.2016-0121TR.

    Article  CAS  PubMed  Google Scholar 

  34. Pan RY, Zhang YD, Zheng M, et al. Hydroxysafflor yellow a suppresses MRC-5 cell activation induced by TGF-beta 1 by blocking TGF-beta 1 binding to T beta RII. Front Pharmacol. 2017;8(12). https://doi.org/10.3389/fphar.2017.00264.

  35. Zhou XM, Wen GY, Zhao Y, et al. Inhibitory effects of alkaline extract of citrus reticulata on pulmonary fibrosis. J Ethnopharmacol. 2013;146(1):372–8. https://doi.org/10.1016/j.jep.2013.01.006.

    Article  PubMed  Google Scholar 

  36. Song JS, Kang CM, Park CK, et al. Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells. Exp Lung Res. 2013;39(8):336–48. https://doi.org/10.3109/01902148.2013.820809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Jiang F, Yang Y, Xue L, et al. 1 alpha,25-dihydroxyvitamin D3 attenuates TGF-beta-induced pro-fibrotic effects in human lung epithelial cells through inhibition of epithelial-mesenchymal transition. Nutrients. 2017;9(9):13. https://doi.org/10.3390/nu9090980.

    Article  CAS  Google Scholar 

  38. Robert S, Gicquel T, Victoni T, et al. Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. Biosci Rep. 2016;36(11). https://doi.org/10.1042/bsr20160107.

  39. Menou A, Duitman J, Crestani B. The impaired proteases and anti-proteases balance in idiopathic pulmonary fibrosis. Matrix Biol. 2018;68–69:382–403. https://doi.org/10.1016/j.matbio.2018.03.001.

    Article  CAS  PubMed  Google Scholar 

  40. Yamashita CM, Radisky DC, Aschner Y, et al. The importance of matrix metalloproteinase-3 in respiratory disorders. Expert Rev Respir Med. 2014;8(4):411–21. https://doi.org/10.1586/17476348.2014.909288.

    Article  CAS  PubMed  Google Scholar 

  41. Wang Y, Huang G, Mo B, et al. Artesunate modulates expression of matrix metalloproteinases and their inhibitors as well as collagen-IV to attenuate pulmonary fibrosis in rats. Genet Mol Res. 2016;15(2):12. https://doi.org/10.4238/gmr.15027530.

    Article  CAS  Google Scholar 

  42. Zhang HT, Fang SC, Wang CY, et al. MMP-9 1562C>T gene polymorphism and efficacy of glucocorticoid therapy in idiopathic pulmonary fibrosis patients. Genet Test Mol Biomark. 2015;19(11):591–7. https://doi.org/10.1089/gtmb.2015.0057.

    Article  CAS  Google Scholar 

  43. Hamburg-Shields E, Dinuoscio GJ, Mullin NK, et al. Sustained beta-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes. J Pathol. 2015;235(5):686–97. https://doi.org/10.1002/path.4481.

    Article  CAS  PubMed  Google Scholar 

  44. Kiszalkiewicz J, Piotrowski WJ, Brzezianska-Lasota E. Signaling pathways and their miRNA regulators involved in the etiopathology of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP). Adv Respir Med. 2017;85(3):169–78. https://doi.org/10.5603/arm.2017.0029.

    Article  PubMed  Google Scholar 

  45. Liu F, Millar SE. Wnt/beta-catenin signaling in oral tissue development and disease. J Dent Res. 2010;89(4):318–30. https://doi.org/10.1177/0022034510363373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–80. https://doi.org/10.1016/j.cell.2006.10.018.

    Article  CAS  PubMed  Google Scholar 

  47. Guo YT, Chen LW, Sun CY, et al. MicroRNA-500a promotes migration and invasion in hepatocellular carcinoma by activating the Wnt/b-catenin signaling pathway. Biomed Pharmacother. 2017;91:13–20. https://doi.org/10.1016/j.biopha.2017.04.018.

    Article  CAS  PubMed  Google Scholar 

  48. Yang SC, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/beta-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017;16:12. https://doi.org/10.1186/s12943-017-0700-1.

    Article  CAS  Google Scholar 

  49. Liu J, Ding X, Tang J, et al. Enhancement of canonical Wnt/beta-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One. 2011;6(11):10. https://doi.org/10.1371/journal.pone.0027496.

    Article  CAS  PubMed Central  Google Scholar 

  50. Burgy O, Konigshoff M. The WNT signaling pathways in wound healing and fibrosis. Matrix Biol. 2018;68–69:67–80. https://doi.org/10.1016/j.matbio.2018.03.017.

    Article  CAS  PubMed  Google Scholar 

  51. Baarsma HA, Konigshoff M. 'WNT-er is coming': WNT signalling in chronic lung diseases. Thorax. 2017;72(8):746–59. https://doi.org/10.1136/thoraxjnl-2016-209753.

    Article  CAS  PubMed  Google Scholar 

  52. Guo Y, Xiao L, Sun L, et al. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012;61(4):337–46.

    Article  CAS  Google Scholar 

  53. Willert K, Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev. 1998;8(1):95–102. https://doi.org/10.1016/s0959-437x(98)80068-3.

    Article  CAS  PubMed  Google Scholar 

  54. Van Der Velden JLJ, Guala AS, Leggett SE, et al. Induction of a mesenchymal expression program in lung epithelial cells by wingless protein (Wnt)/beta-catenin requires the presence of c-Jun N-terminal Kinase-1 (JNK1). Am J Respir Cell Mol Biol. 2012;47(3):306–14. https://doi.org/10.1165/rcmb.2011-0297OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Pappas K, Xu J, Zairis S, et al. p53 maintains baseline expression of multiple tumor suppressor genes. Mol Cancer Res. 2017;15(8):1051–62. https://doi.org/10.1158/1541-7786.Mcr-17-0089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The material and regents required for the research were supported by grants from Science and Technology Planning Project of Zhanjiang (171211161910115/2017A01015), Pearl River S & T Nova Program of Guangzhou (201710010075), Elite Youth Education Program of Guangzhou university of Chinese medicine, Guangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine (2017B030314096) and Major project of Guangdong Province (2014B090902002). Funding body did not involve in the design of the research, data collection, analysis manuscript writing.

Author information

Author notes

  1. Juan Nie and Yanlu Liu contributed equally to this work.

Authors and Affiliations

  1. School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 510006, Guangzhou, China

    Juan Nie, Yanlu Liu, Jingna Zheng, Baoyi Chen, Jianyi Zhuo, Ziren Su, Xiaoping Lai, Jiannan Chen & Yucui Li

  2. 2nd Clinical Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    Chaoyue Sun

  3. Guangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China

    Ziren Su, Xiaoping Lai, Jiannan Chen & Yucui Li

  4. Department of Pharmacy, Central People’s Hospital of Zhanjiang, Zhanjiang, 524000, China

    Jibiao Zheng

Authors
  1. Juan Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanlu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chaoyue Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingna Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Baoyi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jianyi Zhuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ziren Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaoping Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jiannan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jibiao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yucui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LYC designed and supervised the experiments; NJ, SCY, ZJN and CBY conducted the experiments; LYL, ZJY analyzed relevant data; CJN, SZR, LXP. ZJB and LYC contributed to experiment materials. NJ and LYC wrote the paper and processed all figures and tables. All authors have read and approved the final version of the manuscript.

Corresponding authors

Correspondence to Jibiao Zheng or Yucui Li.

Ethics declarations

Ethics approval and consent to participate

Operation of all animal experiments were conducted under the guidance of the ethical standards of the international rules and regulations (GCP, Declaration of Helsinki). The research was conducted with the approve of the Ethics Committee of Guangzhou University of Chinese Medicine, and each experimenter was informed of the relevant precautions.

Consent for publication

All authors consent to publish the study in BMC Complementary Medicine and Therapies.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, J., Liu, Y., Sun, C. et al. Effect of supercritical carbon dioxide fluid extract from Chrysanthemum indicum Linné on bleomycin-induced pulmonary fibrosis. BMC Complement Med Ther 21, 240 (2021). https://doi.org/10.1186/s12906-021-03409-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-021-03409-9

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us